Previous 10 | Next 10 |
home / stock / nvs / nvs articles
German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concern...
Shares of Trevena Inc (NASDAQ:TRVN) are trading lower on Thursday, with a session volume of 23.65 million, as per data from Benzinga Pro. The compa...
Italy’s antitrust regulator has initiated an investigation into several pharmaceutical giants, including Novartis AG (NYSE:NVS) and Roche Hol...
On Friday, Novartis AG (NYSE:NVS) released new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton'...
U.S. drug wholesaler Cencora Inc (NYSE:COR), formerly AmerisourceBergen, is notifying affected individuals about their personal...
Roche (OTC: RHHBY) obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer pat...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo). TAMARA...
Researchers at Alphabet Inc’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google DeepMind have developed AlphaFold 3, an new artificial intelligence (...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...